COVID-19：塩野義、コロナ飲み薬で最終治験：S-２１７６２２（動画）：
COVID-19: Shionogi, final clinical trial with corona drug: S-217622：
COVID-19：Shionogi，电晕药物的最终临床试验：S-217622
塩野義製薬：
COVID-19治療向け飲み薬を開発中。
9月28日、日本で最終段階の臨床試験（治験）を始めたと発表した。
コロナ患者向け飲み薬：
- 投与対象は、
- 軽症や無症状の新型コロナ感染者だ、
- 投与しやすい飲み薬のニーズは大きい。
飲み薬の効能：
塩野義が開発している飲み薬は、「ウイルス増殖に必要な酵素の働きを妨げる」
感染初期に服用して、重症化の抑制と発熱やせきなどを緩和する。
日本経済新聞
https://www.nikkei.com/article/DGXZQOUF282PZ0Y1A920C2000000/
Shionogi starts next phase of oral COVID drug test
Japanese pharmaceutical firm Shionogi
says it has begun a new phase in a clinical trial for an orally administered coronavirus treatment.
The Osaka-based company started first-phase tests in July this year.
The firm says it found no safety problems at that stage.
In the next round of tests that started on Monday,
the company is checking the drug’s efficacy and safety by administering it once a day for five days to COVID-19 patients with mild or no symptoms.
The tests
will target hospitalized patients and those who are recovering at accommodation facilities.
Shionogi
has not disclosed the scale and duration of the trial, but it aims to be ready by the end of this year to produce the drug for one million people.
Japan’s health ministry on Monday
approved sotrovimab, made by the British pharmaceutical giant GlaxoSmithKline,
for non-severe coronavirus cases, following an earlier approval of an antibody cocktail treatment.
Neither are administered orally.
NHK WORLD-JAPAN News